RSS Feed
April 7th, 2016 
Awake Goy
Susanne Posel ,Chief Editor Occupy Corporatism | Media Spokesperson, HEALTH MAX Brands
The Drug Enforcement Administration (DEA) have decided to remove cannabis from the class of Schedule I controlled substances by the end of this year.
Last year Senator Elizabeth Warren and 7 other lawmakers wrote a letter asking the Department of Health and Human Services (HHS), the Office of National Drug Control (ONDC) and the DEA to remove cannabis from the Schedule I and allow for more research into the medicinal purposes of the plant; including the separation of Cannabidiol (CBD) from the Schedule I and the cannabis plant.
In response, those agencies involved said they would provide a rescheduling recommendation by mid-2016.
Last year, researchers Researchers at the NYU Langone Comprehensive Epilepsy Center (LCEC) conducted a study on CBD as an isolate to treat seizure disorders such as epilepsy and found some surprising results.
In the course of the 12 week trial, “more than half of the children and adults treated with [CBD] experienced fewer seizures.”
The participants were given a “99% pure liquid version of the drug was given for three to six months to 137 people with” Dravet or Lennox-Gastaut syndromes.
The majority of the volunteers were children, ages 2 to 26, and suffered from an average of 95 convulsive seizures a month.
Side effects, such as drowsiness, nausea, decreased appetite and diarrhea were reported by participants which may have contributed to the “relatively high dropout” rate for the trial.
Seventy-six of the 213 patients ages 2 to 42 did not complete the trail. And of the 137 remaining volunteers, 54% “saw a reduction in epileptic seizures”.
GW Pharmaceuticals, a bio-tech corporation invested in cannabidiol research, provided the CBD isolate called Epidiolex for this study. Their CBD isolate was devoid of THC and provided the possibility of benefiting from the CBD without getting the patient high.
This study is part of a larger research initiative of GW to get their product ready for approval by the Food and Drug Administration (FDA). Because GW is the manufacturer of Epidiolex, they are prohibited from making health claims about their product per regulations set forth by the FDA.
However, with GW providing the isolate CBD for the LCEC study, they have effectively proved the health claims that can be attributed to their product without having to make those statements themselves. GW can simply refer to this study to show Epidiolex is effective in treating Dravet or Lennox-Gastaut syndromes.
Recently alternative media tabloid Natural News stunned the CBD industry by publishing a story alleging the Food and Drug Administration (FDA) is “trying to destroy the CBD industry with regulatory assaults” by outlawing it.
Adams jumped to conclusions because of his preconceived belief that the “FDA essentially writes its own regulatory laws” for writing letters to companies that sell CBD products.
The facts Adams conveniently omitted from his story was that the FDA had warned snakeoil CBD retailers that they were using false marketing tactics to sell sub-par products.
These retailers sold CBD products that either did not contain CBD or contained a fraction of the percentage advertised. In addition, the hemp paste used in this products is imported from China and filled with toxic solvents, heavy metals, and LIVE microbial life.
Perhaps the fact that one of the companies named by the FDA as selling fake CBD tincture advertises on Adams website might have contributed to the sensational story he published.
Related Posts
Source Article from http://feedproxy.google.com/~r/OccupyCorporatism/~3/Gth4uSDBO24/
Posted in 
Tags: 
